Skip to main content
Veterinary Medicines

NEOCAL 300

Authorised
  • Calcium gluconate
  • CALCIUM GLYCEROPHOSPHATE
  • Magnesium chloride hexahydrate
  • Caffeine

Product identification

Medicine name:
НЕОКАЛ 300
NEOCAL 300
Active substance:
  • Calcium gluconate
  • CALCIUM GLYCEROPHOSPHATE
  • Magnesium chloride hexahydrate
  • Caffeine
Target species:
  • Horse
  • Cattle
  • Sheep
  • Goat
  • Pig
  • Dog
  • Cat
Route of administration:
  • Intravenous use
  • Subcutaneous use

Product details

Active substance and strength:
  • Calcium gluconate
    160.00
    milligram(s)
    /
    1.00
    millilitre(s)
  • CALCIUM GLYCEROPHOSPHATE
    66.00
    milligram(s)
    /
    1.00
    millilitre(s)
  • Magnesium chloride hexahydrate
    64.00
    milligram(s)
    /
    1.00
    millilitre(s)
  • Caffeine
    20.00
    milligram(s)
    /
    1.00
    millilitre(s)
Pharmaceutical form:
  • Solution for injection
Withdrawal period by route of administration:
  • Intravenous use
    • Horse
    • Cattle
    • Sheep
    • Goat
    • Pig
    • Dog
    • Cat
  • Subcutaneous use
    • Horse
      • Meat and offal
        0
        day
    • Cattle
      • Meat and offal
        0
        day
    • Sheep
      • Meat and offal
        0
        day
    • Goat
      • Meat and offal
        0
        day
    • Pig
      • Meat and offal
        0
        day
    • Dog
    • Cat
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QA12AX
Authorisation status:
  • Valid
Authorised in:
  • Bulgaria
Package description:

Additional information

Entitlement type:
  • Marketing Authorisation
Marketing authorisation holder:
  • Dsm Denitrans OOD
Marketing authorisation date:
Manufacturing sites for batch release:
  • Dsm Denitrans OOD
Responsible authority:
  • Bulgarian Agency For Food Safety
Authorisation number:
  • 0022-2872
Date of authorisation status change:

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
Bulgarian (PDF)
Published on: 17/01/2023
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."